A non-peptide, orally active ghrelin mimetic that achieves what most growth hormone secretagogues cannot — meaningful GH and IGF-1 elevation after oral administration, making it a uniquely practical research tool.
MK-677, also known as Ibutamoren, is genuinely unusual in this research library: it's not technically a peptide at all. While every other compound in the Growth Hormone Secretagogue category is a peptide (strings of amino acids), MK-677 is a small organic molecule — a non-peptide ghrelin receptor agonist developed by Merck. This distinction matters enormously for research applications. Peptide GH secretagogues like GHRP-6 and Ipamorelin are rapidly degraded in the stomach and must be administered by injection to be effective. MK-677 is orally active, meaning it survives digestion and reaches the bloodstream after oral administration — making it one of the only orally bioavailable GH secretagogues studied in humans.
Developed in the mid-1990s, MK-677 was extensively studied in clinical trials by Merck for GH deficiency, aging-related muscle loss (sarcopenia), and other conditions involving low IGF-1. Merck ultimately didn't advance it to regulatory approval, but the clinical data generated — including multiple published trials in elderly populations showing sustained IGF-1 elevation over months — makes it one of the most clinically characterized GH secretagogues in existence.
MK-677 is a ghrelin mimetic — it binds to the ghrelin receptor (GHS-R1a) and activates the same signaling cascade as ghrelin itself, stimulating growth hormone release from pituitary somatotrophs. But because it's a small organic molecule rather than a peptide, it's designed to survive oral absorption: it's resistant to stomach acid degradation, absorbs through the intestinal wall, and reaches systemic circulation intact. Once absorbed, MK-677 has a long half-life (approximately 5–6 hours) compared to injectable GHRPs, producing more sustained GH and IGF-1 elevation.
The sustained nature of its activity means it produces a less pulsatile, more tonic GH secretion pattern than short-acting injectable GHRPs — which has been the focus of some research comparing the biological differences between pulsatile and sustained GH signaling.
Imagine the ghrelin receptor as a doorbell that, when pressed, signals the pituitary to release GH. Peptide GHRPs are like having someone knock on the door — effective but only if you're standing right there, and the knocking stops quickly. MK-677 is like wiring up an automated doorbell that rings at regular intervals all day on its own after you press the button once in the morning. You still ring the same doorbell (same receptor), but the delivery mechanism is completely different — persistent, oral, long-lasting.
Investigación Renuncia de responsabilidad: Lo siguiente refleja investigación clínica y preclínica publicada y no es consejo médico. Consulta a un profesional de la salud licenciado antes de tomar decisiones de salud.
MK-677 (Ibutamoren) has one of the most extensive published human clinical datasets of any research secretagogue — Merck conducted 12+ published trials across multiple indications including GH deficiency, aging, bone density, and cachexia.
Referencias Clave: Chapman IM et al. (1996). MK-677 in elderly adults. J Clin Endocrinol Metab. · Svensson J et al. (1998). MK-677 in obese subjects. J Clin Endocrinol Metab. · Murphy MG et al. (1999). MK-677 in hip fracture. J Clin Endocrinol Metab.
Merck ran over a dozen clinical trials with MK-677, some lasting up to 2 years. The compound made it all the way to Phase II/III but was ultimately not approved — the trials showed it worked (it raised IGF-1 reliably) but the risk-benefit profile for the specific indications studied wasn't compelling enough for a new drug application. The data remains published and accessible.
MK-677 is the subject of significant research interest specifically because it's orally active. The challenge of making peptide drugs orally bioavailable is one of the central problems in pharmaceutical science — peptides get destroyed in the gut. MK-677 "cheats" by not being a peptide at all, bypassing this problem entirely.
MK-677 has been studied for its effects on sleep architecture — growth hormone is predominantly released during slow-wave sleep, and some research in elderly subjects found MK-677 administration increased REM sleep duration and slow-wave activity, consistent with elevated GH secretion patterns.
Every batch of MK-677 (Ibutamoren) with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.